Breaking News, Collaborations & Alliances

Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration

Expands existing contract manufacturing deal to further enable global manufacture of ublituximab.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Samsung Biologics, a contract development and manufacturing organization (CDMO) and TG Therapeutics, are expanding a large-scale contract manufacturing deal for the supply of TG Therapeutics’ ublituximab, an investigational anti-CD20 monoclonal antibody.   TG Therapeutics has completed a rolling submission of a Biologics License Application (BLA) to the U.S. FDA requesting approval of ublituximab, in combination with UKONIQ (umbralisib), TG Therapeutics’ oral once-daily inhibitor of PI3K-delta...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters